Download Image
    
Share
  
Post
Antroquinonol for COVID-19
1 study with 124 patients
Hospital Icon Control
Hospital Icon Antroquinonol Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Antroquinonol studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -200% Hospitalization 2% Viral clearance 7% RCTs -200% Late -200% Favorsantroquinonol Favorscontrol
Antroquinonol is an orally administered small molecule, isolated from Antrodia camphorata, with anti-inflammatory and potential antiviral activity.
Dec 23
2021
 Cheng et al., NCT04523181 A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19
200% higher progression (p=1), 17% slower recovery (p=0.72), 2% shorter hospitalization (p=0.92), and 7% faster viral clearance (p=0.87). RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol.